UBT251

UBT251

Evidence & Status

  • Moderate Evidence
  • Moderate

At a Glance

An investigational GLP-1/GIP/glucagon triple-agonist peptide with early randomized human weight-management research.

Plain English

UBT251 is being studied for weight management. Early trials reported weight changes and gastrointestinal adverse events, but those short studies cannot predict an individual's benefit or establish long-term safety.

Overview

UBT251 is an investigational peptide agonist of GLP-1, GIP and glucagon receptors. A randomized, double-blind, placebo-controlled Phase 1a/1b publication studied subcutaneous administration, with safety and tolerability as primary endpoints. These early studies do not establish an approved obesity treatment or long-term efficacy and safety.

Research Summary

The Phase 1a study evaluated single ascending subcutaneous doses; the Phase 1b study evaluated 12 weeks of once-weekly treatment in participants with overweight or obesity without diabetes. In the reported active-dose groups, mean weight reductions ranged from 8.96 to 13.48 kg, compared with a 1.57 kg increase with placebo. Laboratory investigations, decreased appetite and gastrointestinal adverse events were the most commonly reported adverse effects. Approximately linear pharmacokinetics were reported within the studied 1.0–6.0 mg range; this is study-specific, not a dosing recommendation. This record does not use conference-only Phase 2 efficacy claims or establish long-term benefit or safety.

Research Areas

  • Obesity research
  • Weight management
  • GLP-1/GIP/glucagon receptor research

Safety & Risks

Reported Side Effects

  • Gastrointestinal adverse events
  • Decreased appetite
United States
Investigational research; no approved clinical use is asserted by this record.
United Kingdom
Current authorization status not established in this record.
Australia
Current authorization status not established in this record.
Canada
Current authorization status not established in this record.

Citations & Sources